LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 129

Search options

  1. Article ; Online: Preoperative anemia in major elective surgery.

    Skorupski, Clarissa P / Cheung, Matthew C / Lin, Yulia

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    2023  Volume 195, Issue 15, Page(s) E551

    MeSH term(s) Humans ; Anemia/therapy ; Elective Surgical Procedures ; Preoperative Care
    Language English
    Publishing date 2023-04-17
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 215506-0
    ISSN 1488-2329 ; 0008-4409 ; 0820-3946
    ISSN (online) 1488-2329
    ISSN 0008-4409 ; 0820-3946
    DOI 10.1503/cmaj.221635
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: [No title information]

    Skorupski, Clarissa P / Cheung, Matthew C / Lin, Yulia

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    2023  Volume 195, Issue 31, Page(s) E1059–E1060

    Title translation Anémie préopératoire dans le contexte d’une intervention chirurgicale importante non urgente.
    Language French
    Publishing date 2023-08-15
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 215506-0
    ISSN 1488-2329 ; 0008-4409 ; 0820-3946
    ISSN (online) 1488-2329
    ISSN 0008-4409 ; 0820-3946
    DOI 10.1503/cmaj.221635-f
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Vitamin B

    Silverstein, William K / Cheung, Matthew C / Lin, Yulia

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    2022  Volume 194, Issue 24, Page(s) E843

    MeSH term(s) Humans ; Vitamin B 12/therapeutic use ; Vitamin B 12 Deficiency/complications ; Vitamin B 12 Deficiency/diagnosis ; Vitamins
    Chemical Substances Vitamins ; Vitamin B 12 (P6YC3EG204)
    Language English
    Publishing date 2022-06-17
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 215506-0
    ISSN 1488-2329 ; 0008-4409 ; 0820-3946
    ISSN (online) 1488-2329
    ISSN 0008-4409 ; 0820-3946
    DOI 10.1503/cmaj.220306
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: [No title information]

    Silverstein, William K / Cheung, Matthew C / Lin, Yulia

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    2022  Volume 194, Issue 37, Page(s) E1300–E1301

    Title translation Carence en vitamine B
    MeSH term(s) Humans ; Vitamin B 12 ; Vitamin B 12 Deficiency
    Chemical Substances Vitamin B 12 (P6YC3EG204)
    Language French
    Publishing date 2022-09-23
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 215506-0
    ISSN 1488-2329 ; 0008-4409 ; 0820-3946
    ISSN (online) 1488-2329
    ISSN 0008-4409 ; 0820-3946
    DOI 10.1503/cmaj.220306-f
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Augmenting clinical trial economic analysis by linking cancer trial data to administrative data: current landscape and future opportunities.

    Wilson, Brooke E / Hay, Annette E / Chan, Kelvin Kar-Wing / Cheung, Matthew C / Hanna, Timothy P

    BMJ open

    2023  Volume 13, Issue 8, Page(s) e073353

    Abstract: Background: Economic analyses based on clinical trial data are costly and time consuming, and alternative methods for performing economic analyses should be explored.: Objective and methods: In this perspective, we examine the emerging role of ... ...

    Abstract Background: Economic analyses based on clinical trial data are costly and time consuming, and alternative methods for performing economic analyses should be explored.
    Objective and methods: In this perspective, we examine the emerging role of administrative data for economic analyses in cancer.
    Results: Compared with routinely collected clinical trial data, routinely collected administrative data have several strengths including high capture rates for healthcare encounters, less resource utilisation, low rates of misclassification, long follow-up periods and the opportunity to collect data points not traditionally captured in clinical trials. However, there are also limitations including the need for accurate data linkage across multiple databases and systems, the costs and time associated with data linkage, the potential time lag between trial data collection and the availability of administrative data, and limited data on quality of life, toxicity and indirect costs. In this perspective, we identify important barriers and potential solutions to performing economic analyses for oncology using administrative data, and outline strategies to increase research in this field.
    Conclusion: The use of routinely collected administrative data sets for economic analyses of clinical trials presents a unique opportunity that could complement and validate economic analyses based on trial-level data.
    MeSH term(s) Humans ; Quality of Life ; Neoplasms/therapy ; Data Collection ; Cost-Benefit Analysis
    Language English
    Publishing date 2023-08-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2599832-8
    ISSN 2044-6055 ; 2044-6055
    ISSN (online) 2044-6055
    ISSN 2044-6055
    DOI 10.1136/bmjopen-2023-073353
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.

    Everest, Louis / Chen, Bingshu E / Hay, Annette E / Cheung, Matthew C / Chan, Kelvin K W

    BMC medical research methodology

    2023  Volume 23, Issue 1, Page(s) 179

    Abstract: Background: Historically, a priori power and sample size calculations have not been routinely performed cost-effectiveness analyses (CEA), partly because the absence of published cost and effectiveness correlation and variance data, which are essential ... ...

    Abstract Background: Historically, a priori power and sample size calculations have not been routinely performed cost-effectiveness analyses (CEA), partly because the absence of published cost and effectiveness correlation and variance data, which are essential for power and sample size calculations. Importantly, the empirical correlation between cost and effectiveness has not been examined with respect to the estimation of value-for-money in clinical literature. Therefore, it is not well established if cost-effectiveness studies embedded within randomized-controlled-trials (RCTs) are under- or over-powered to detect changes in value-for-money. However, recently guidelines (such as those from ISPOR) and funding agencies have suggested sample size and power calculations should be considered in CEAs embedded in clinical trials.
    Methods: We examined all RCTs conducted by the Canadian Cancer Trials Group with an embedded cost-effectiveness analysis. Variance and correlation of effectiveness and costs were derived from original-trial data. The incremental net benefit method was used to calculate the power of the cost-effectiveness analysis, with exploration of alternative correlation and willingness-to-pay values.
    Results: We identified four trials for inclusion. We observed that a hypothetical scenario of correlation coefficient of zero between cost and effectiveness led to a conservative estimate of sample size. The cost-effectiveness analysis was under-powered to detect changes in value-for-money in two trials, at willingness-to-pay of $100,000. Based on our observations, we present six considerations for future economic evaluations, and an online program to help analysts include a priori sample size and power calculations in future clinical trials.
    Conclusion: The correlation between cost and effectiveness had a potentially meaningful impact on the power and variance of value-for-money estimates in the examined cost-effectiveness analyses. Therefore, the six considerations and online program, may facilitate a priori power calculations in embedded cost-effectiveness analyses in future clinical trials.
    MeSH term(s) Humans ; Cost-Effectiveness Analysis ; Sample Size ; Canada ; Neoplasms/therapy ; Cost-Benefit Analysis
    Language English
    Publishing date 2023-08-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041362-2
    ISSN 1471-2288 ; 1471-2288
    ISSN (online) 1471-2288
    ISSN 1471-2288
    DOI 10.1186/s12874-023-01956-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Fracture risk among patients with cancer compared to individuals without cancer: a population-based study.

    Gong, Inna Y / Chan, Kelvin K W / Lipscombe, Lorraine L / Cheung, Matthew C / Mozessohn, Lee

    British journal of cancer

    2023  Volume 129, Issue 4, Page(s) 665–671

    Abstract: Background: Patients with cancer may be at increased risk of osteoporosis and fracture; however, gaps exist in the existing literature and the association between cancer and fracture requires further examination.: Methods: We conducted a population- ... ...

    Abstract Background: Patients with cancer may be at increased risk of osteoporosis and fracture; however, gaps exist in the existing literature and the association between cancer and fracture requires further examination.
    Methods: We conducted a population-based cohort study of Ontario patients with cancer (breast, prostate, lung, gastrointestinal, haematologic) diagnosed between January 2007 to December 2018 and 1:1 matched non-cancer controls. The primary outcome was incident fracture (end of follow-up December 2019). Multivariable Cox regression analysis was used to estimate the relative fracture risk with sensitivity analysis accounting for competing risk of death.
    Results: Among 172,963 cancer patients with non-cancer controls, 70.6% of patients with cancer were <65 years old, 58% were female, and 9375 and 8141 fracture events were observed in the cancer and non-cancer group, respectively (median follow-up 6.5 years). Compared to non-cancer controls, patients with cancer had higher risk of fracture (adjusted HR [aHR] 1.10, 95% CI 1.07-1.14, p < 0.0001), which was also observed for both solid (aHR 1.09, 95% CI 1.05-1.13, p < 0.0001) and haematologic cancers (aHR 1.20, 95% CI 1.10-1.31, p < 0.0001). Sensitivity analysis accounting for competing risk of death did not change these findings.
    Conclusions: Our study indicates that patients with cancer are at modest risk of fractures compared to non-cancer controls.
    MeSH term(s) Male ; Humans ; Female ; Aged ; Cohort Studies ; Proportional Hazards Models ; Fractures, Bone/epidemiology ; Fractures, Bone/etiology ; Risk ; Neoplasms/epidemiology ; Neoplasms/complications ; Risk Factors ; Incidence
    Language English
    Publishing date 2023-07-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-023-02353-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Statins in mature B-cell lymphomas and leukaemias.

    Smyth, Liam / Blunt, Danielle N / Cheung, Matthew C

    British journal of haematology

    2021  Volume 195, Issue 4, Page(s) 490–492

    MeSH term(s) Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Leukemia ; Lymphoma, B-Cell/drug therapy ; Lymphoma, Non-Hodgkin
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2021-08-16
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17778
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: CAR T-cells: costs, comparisons, and commentary.

    Hay, Annette E / Cheung, Matthew C

    Journal of medical economics

    2019  Volume 22, Issue 7, Page(s) 613–615

    MeSH term(s) Cost-Benefit Analysis ; Humans ; Lymphoma, B-Cell ; T-Lymphocytes ; United States
    Language English
    Publishing date 2019-03-21
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2270945-9
    ISSN 1941-837X ; 1369-6998
    ISSN (online) 1941-837X
    ISSN 1369-6998
    DOI 10.1080/13696998.2019.1582059
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study.

    Arya, Sumedha / Mozessohn, Lee / Gong, Inna / Faught, Neil / Liu, Ning / Singh, Simron / Chan, Kelvin / Cheung, Matthew C

    Leukemia & lymphoma

    2024  Volume 65, Issue 5, Page(s) 629–637

    Abstract: The aim of this study was to describe the impact of marginalization on DLBCL overall survival (OS) within the Canadian setting. We conducted a population-based retrospective cohort study of adult patients with newly diagnosed DLBCL in Ontario between 1 ... ...

    Abstract The aim of this study was to describe the impact of marginalization on DLBCL overall survival (OS) within the Canadian setting. We conducted a population-based retrospective cohort study of adult patients with newly diagnosed DLBCL in Ontario between 1 January 2005 and 31 December 2017 receiving a rituximab-containing chemotherapy regimen with curative intent followed until 1 March 2020. Our primary exposure of interest was the Ontario Marginalization Index (ON-Marg). The primary outcome was 2-year OS, accounting for patient age, sex, cancer characteristics, comorbidity burden, and rural dwelling status. While two-year overall survival was inferior for individuals in the most deprived marginalization quintile (70.4% Q5 vs. 76.0% Q1), after adjustment for relevant covariates neither the composite ON-Marg nor any of its dimensions had a significant effect. Within the Canadian context, among patients who receive chemotherapy, marginalization may not have a significant association with overall survival when accounting for key patient covariates, lending support for preserved outcomes.
    MeSH term(s) Humans ; Male ; Female ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/epidemiology ; Retrospective Studies ; Aged ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Adult ; Ontario/epidemiology ; Social Marginalization ; Aged, 80 and over ; Prognosis ; Survival Rate ; Rituximab/therapeutic use ; Rituximab/administration & dosage ; Young Adult
    Chemical Substances Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2024-01-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2024.2306463
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top